$1.84
1.66% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US14757U1097
Symbol
CASI

CASI Pharmaceuticals Inc Stock price

$1.84
-0.25 11.96% 1M
-0.15 7.54% 6M
-0.99 34.98% YTD
-3.74 67.03% 1Y
-0.40 17.86% 3Y
-14.86 88.98% 5Y
-11.97 86.68% 10Y
-265.46 99.31% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+0.03 1.66%
ISIN
US14757U1097
Symbol
CASI
Industry

Key metrics

Basic
Market capitalization
$28.5m
Enterprise Value
$40.8m
Net debt
$12.2m
Cash
$6.8m
Shares outstanding
15.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.9 | 2.7
EV/Sales
1.3 | 3.8
EV/FCF
-
P/B
negative
Financial Health
Equity Ratio
3.5%
Return on Equity
-2,120.9%
ROCE
610.8%
ROIC
-
Debt/Equity
-1.0
Financials (TTM | estimate)
Revenue
$31.6m | $10.6m
EBITDA
- | -
EBIT
$-42.8m | $-34.6m
Net Income
$-46.5m | $-35.3m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
36.7% | -62.8%
EBITDA
- | -
EBIT
-55.6% | -0.4%
Net Income
-71.0% | 10.0%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
56.2%
EBITDA
- | -
EBIT
-135.4%
Net
-147.3% | -332.7%
Free Cash Flow
-
More
EPS
$-2.9
FCF per Share
-
Short interest
1.8%
Employees
233
Rev per Employee
$120.0k
Show more

Is CASI Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

CASI Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a CASI Pharmaceuticals Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a CASI Pharmaceuticals Inc forecast:

Buy
86%
Hold
14%

Financial data from CASI Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
32 32
37% 37%
100%
- Direct Costs 14 14
38% 38%
44%
18 18
35% 35%
56%
- Selling and Administrative Expenses 45 45
18% 18%
144%
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -43 -43
56% 56%
-135%
Net Profit -47 -47
71% 71%
-147%

In millions USD.

Don't miss a Thing! We will send you all news about CASI Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CASI Pharmaceuticals Inc Stock News

Neutral
Accesswire
20 days ago
- Industry veteran brings over 35 years of biotech experience as a successful entrepreneur and investor - Operating experience to significantly enhance development program of CID-103 (anti-CD38 mAb) SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 26, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for p...
Neutral
Accesswire
about one month ago
- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody - Safety profile observed in first four dose cohorts supports continued development - No serious adverse events or dose-limiting toxicities have been reported SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical comp...
Neutral
Accesswire
about one month ago
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference on ...
More CASI Pharmaceuticals Inc News

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.

Head office United States
CEO Wei He
Employees 233
Founded 1991
Website www.casipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today